Nordic Life Science magazine, the leading Nordic life science business magazine, has in an article cited Brain+ and the company’s CST Assistant as an example of an impactful health tech intervention in Alzheimer’s disease. Alzheimer’s disease is the worldwide primary cause of dementia. This public recognition of Brain+ and the company’s health tech solutions is important to increase awareness in the life science industry and among life science investors.   

The article describes how new health technologies enable new forms of treatment of Central Nervous System (CNS) disorders, a medical field that has so far been little understood and not treatable by medical science. It also argues, however, how new methods and technologies are rapidly creating new options for better CNS diagnostics tools and treatments. In this context, the article refers to the Brain+ CST-Assistant as an example of a relevant option for software-enabled delivery of Cognitive Stimulation Therapy (CST) for dementia.  

Quote from the Nordic Life Science Magazine article on the CST-Assistant from Brain+:
“Digital interventions are having an impact on CNS disease treatments as well. For example, the Danish Brain+ CST Assistant, a dementia treatment developed in conjunction with VIA University College, is a collection of cognitive stimulation therapies delivered digitally.” 

Johan Luthman, Interim Chairman of Brain+’ Board of Directors and Executive Vice President & Head of R&D in Lundbeck A/S said with reference to the article:
“There is a great need for varied approaches to managing dementia. This includes using health technologies, like the CST-Assistant, that can enable effective treatment with Cognitive Stimulation Therapy. I believe that Brain+’ software enabled CST can make a large impact on global dementia management, both on its own, and in the future also in combination treatments with pharmaceuticals.” 

Johan Luthman has extensive insight into the field of dementia treatment and played an important role in the development of the last two Alzheimer’s disease drugs, which were approved by the Food and Drug Administration (FDA) for marketing in the U.S., one disease modifying treatment and one symptomatic treatment.  

The article from Nordic Life Science Magazine compares Alzheimer’s disease to the area of oncology (cancer). Dr. Benedict C. Albensi, Professor and Chair of the Department of Pharmaceutical Sciences at Nova Southeastern University, anticipates a near future that will realize a far more complex understanding of Alzheimer’s not as a single disease, but as a category, with more effective treatments as a result. Brain+ soft-ware products delivering CST is highlighted as one of these treatments.   

The novelty of the Brain+ products are in the effective standardized software enabled delivery of Cognitive Stimulation Therapy because CST has been around for 20 years and is the most proven non-pharmaceutical therapy today. The software-based delivery of CST via software applications is a way of increasing the cost-efficiency of delivery, standardizing, improving quality, and allowing effective personalization of treatment. In other words, software based delivery of CST is major step in maturing a proven treatment, following in the footsteps of other disease areas with successful health tech enabled treatments, such as digital diabetes management and software delivered cognitive behavioural therapy in mental health.  

Contact Information
CEO and Co-founder: Kim Baden-Kristensen, + 45 31393317 (SMS), kim@brain-plus.com 

Brain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, serving several million people affected by dementia by 2030. 

About Nordic Life Science magazine
Nordic Life Science magazine, founded in 2007, is well established as the leading Nordic life science business magazine. With high editorial credibility, our hand-picked team of experts, editors and journalists serve our subscribers a reading experience of highest quality and a greater comprehension and explanation of the Nordic life science industry. 

Source article:
The original article which is referenced here was originally published in NLS magazine No 01 2024. Additional perspectives in this release have been added by Brain+.  

About the author of the article: 
Sheila Mahoney-Jewels, MBA, is a Drug Development Cross-Functionalist and Science Writer. She is heavily involved in industry adoption of advanced safety analytics, data science and application of AI and ML to drug development operations.